Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : PJ November 2015 online

Sort by: Newest first Oldest first A-Z Z-A

  • New indication for Eylea Subscription

    16 NOV 2015 16:22

    Eylea (aflibercept; Bayer) is now indicated for visual impairment due to myopic choroidal neovascularisation. Further changes to the summary of product characteristics reflect this addition. 

  • Dinutuximab not recommended in draft NICE guidance Subscription

    16 NOV 2015 16:10

    The National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend dinutuximab (when used in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and isotretinoin) as a treatment for high-risk neuroblastoma for children and young people between the ages of 12 months and 17 years.

  • Intensive blood pressure (BP) reduction is more beneficial for patients than less intensive BP reduction, concludes research. In the image, woman takes her blood pressure

    Intensive lowering of blood pressure cuts heart attacks and strokes, review says Subscription

    16 NOV 2015 15:36 By Bea Perks

    Intensive blood pressure reduction is more beneficial for patients than less intensive BP reduction, concludes a review published in The Lancet.

  • New commercial deals with pharmaceutical companies are being proposed to give NHS patients quicker access to innovative drugs before evidence shows their long-term benefit. In the image, close-up of a scientist working in a laboratory

    Government ponders new access models for innovative drugs Subscription

    13 NOV 2015 16:41 By Debbie Andalo

    Commercial deals with pharmaceutical companies are being proposed to speed up NHS patients’ access to innovative drugs before evidence shows their long-term benefit.

  • Research found a small-to-moderate benefit of omega-3 supplementation (pictured) on depressive symptoms compared with placebo, but concluded that the magnitude was unlikely to be clinically meaningful.

    Not enough evidence for omega-3 supplementation in depression Subscription

    13 NOV 2015 15:31

    Cochrane review says more evidence is needed on omega-3’s role in major depression before firm conclusions are drawn.

  • Eviplera side effects Subscription

    13 NOV 2015 14:58

    Severe skin reactions is now listed as an uncommon adverse reaction in the summary of product characteristics for Eviplera (emtricitabine, rilpivirine, tenofovir disoproxil; Gilead).

  • Relpax back in stock Subscription

    13 NOV 2015 14:50

    Relpax (eletriptan hydrobromide) film-coated tablets 40mg are now back in stock from Pfizer.

  • Errors in the BNF for Children Subscription

    13 NOV 2015 14:40

    An error has been found in the new British National Formulary (BNF) for Children (2015–2016) regarding the indications of aciclovir. Some indications are omitted or are unclear.

  • Confusing sulfadiazine with sulfasalazine Subscription

    Computerised prescribing systems make it all too easy to give patients sulfadiazine (a treatment for rheumatic fever and toxoplasmosis) instead of sulfasalazine (a treatment for rheumatoid arthritis). Similar dosing and adjacent keyboard letters D and S may exacerbate this. In our region, three patients have experienced this error and in two of the cases it has taken over a year for the patient or their doctors to pick up this error. Prescribers and pharmacists need to be wary of this ...

  • Local practice forum event: 16 December 2015 Subscription

    13 NOV 2015 14:33

    Wednesday 16 December: London North Local practice forum event, ‘Assisted Dying’. Larches Community Hall, 1 Rectory Lane, Edgware, London HA8 7LF. Event 8pm, buffet 7.15pm. No booking required, just turn up.  

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.